<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sweeney, Christopher</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Docetaxel at Beginning of Androgen Deprivation Therapy Boosts Overall Survival by over 1 Year</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results of the Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer trial [CHAARTED; NCT00309985]. The trial demonstrated that the use of docetaxel at the beginning of androgen deprivation therapy (ADT) increases overall survival (OS) in patients with metastatic prostate cancer by &gt;1 year compared with ADT alone.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>